Antidepressants and hypothalamic-pituitary-adrenocortical regulation.
Endocr Rev 1996;17:187–205.
The corticosteroid receptor hypothesis of depression.
The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions.
Mol Psychiatry 1996;1:336–342.
4.De Kloet, ER,
Brain corticosteroid receptor balance in health and disease.
Endocr Rev 1998;19:269–301.
De Kloet, ER.
Corticosterone and serotonergic neurotransmission in the hippocampus: functional implications of central corticosteroid receptor diversity.
Crit Rev Neurobiol 1998;12:1–20.
Ketoconazole administration in hypercortisolemic depression.
Am J Psychiatry 1993;150:810–812.
Abnormalities of the HPA axis in affective disorders: clinical subtypes and potential treatments.
Acta Neuropsychiatrica 2006;18:193–209.
8.van Rossum, EF,
van Den Beld, AWet al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index.
Clin Endocrinol 2003;59:585–592.
9.van Rossum, EF,
Huizenga, NAet al. A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels.
De Lange, Pet al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo.
J Clin Endocrinol Metab 1998;83:144–151.
11.van Rossum, EF,
Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition.
Recent Prog Horm Res 2004;59:333–357.
De Lange, Pet al. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance.
Hum Genet 1997;99:663–668.
Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 2004;29:423–447.
Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder.
Brain Res 2006;1118:176–182.
Paik, JWet al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population.
Prog Neuropsychopharmacol Biol Psychiatry 2007;31:104–107.
Structured clinical interview for DSM-IV axis I disorder-Korean version. Seoul: Hana Medical Publishing Co, 2000.
Development of a rating scale for primary depressive illness.
Br J Soc Clin Psychol 1967;6:278–296.
Jarrett, RBet al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.
Arch Gen Psychiatry 1991;48:851–855.
An inventory for measuring depression.
Arch Gen Psychiatry 1961;4:561–571.
20.van Rossum, EF,
Majer, Met al. Polymorphisms of the glucocorticoid receptor gene and major depression.
Biol Psychiatry 2006;59:681–688.
Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression.
Curr Opin Pharmacol 2002;2:23–33.
Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load.
Holm, Get al. A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis.
Obes Res 2000;8:211–218.
van Rossum, EFet al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression.
25.van West, D,
van Den Eede, F,
Del-Favero, Jet al. Glucocorticoid receptor gene-based SNP analysis in patients with recurrent major depression.
The DST as a predictor of outcome in depression: a meta-analysis.
Am J Psychiatry 1993;150:1618–1629.
Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study.
J Psychiatr Res 2001;35:83–94.
Local DNA demethylation in vertebrates: how could it be performed and targeted? FEBS Lett 2001;494:135–140.
5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study.
J Clin Psychopharmacol 2003;23:563–567.